{{Rsnum
|rsid=2636802
|Gene=SLIT1
|Chromosome=10
|position=98930392
|Orientation=minus
|GMAF=0.3264
|Gene_s=ARHGAP19-SLIT1,SLIT1
|Assembly=GRCh37.p5
|GenomeBuild=37.3
|dbSNPBuild=137
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 4.4 | 32.7 | 62.8
| HCB | 13.1 | 48.9 | 38.0
| JPT | 23.9 | 39.8 | 36.3
| YRI | 24.7 | 51.4 | 24.0
| ASW | 33.9 | 41.1 | 25.0
| CHB | 13.1 | 48.9 | 38.0
| CHD | 11.9 | 51.4 | 36.7
| GIH | 10.9 | 38.6 | 50.5
| LWK | 27.3 | 50.0 | 22.7
| MEX | 10.5 | 31.6 | 57.9
| MKK | 27.7 | 51.0 | 21.3
| TSI | 1.0 | 36.6 | 62.4
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2636802
|Name_s=
|Gene_s=SLIT1
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 89. Study population/ethnicity: 89 Yorubans. Significance metric(s): p = 0.00004. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109517
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2636802
|overall_frequency_n=76
|overall_frequency_d=128
|overall_frequency=0.59375
|n_genomes=42
|n_genomes_annotated=0
|n_haplomes=63
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}